Mirabegron And Ureteral Stent-related Pain (MAP) Trial
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Nephrolithiasis
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: This study is a randomized, placebo-controlled, double blinded trial.Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04286152
- Collaborators
- Canadian Urological Association
- Investigators
- Principal Investigator: Michael Ordon, MD, FRCSC St. Michael's Hospital, Unity Health Toronto